At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at the Sylvester Comprehensive Cancer Center, University of Miami, engaged in a discussion about the final analysis of the Sinterra study. The study, a randomized phase two trial, aimed to assess the efficacy and safety of daratumumab monotherapy in patients with intermediate or high-risk smoldering multiple myeloma.
Dr. Landgren outlined the international multicenter nature of the trial and its objective to investigate whether daratumumab could delay or prevent the progression from smoldering myeloma to multiple myeloma.